The Latest Cardiac and Vascular News
— Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds — — Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and other engineered tissue platform applications — DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology […]
Humacyte raises $245M gross proceeds Combined company is expected to begin trading on the Nasdaq Global Select Market® under “HUMA” and “HUMAW” on August 27, 2021 Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial disease Combined […]
NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) — Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue […]
Appoints proven commercial leader B.J. Scheessele as Chief Commercial Officer In-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale manufacturing system Company’s proprietary modular manufacturing systems can produce an estimated 40,000+ vessels annually in current facility when scaled up DURHAM, N.C., Aug. 17, 2021 (GLOBE […]
Proven CFO with extensive financial leadership and commercialization experience, including multiple publicly listed life sciences companies DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Dale Sander as Chief Financial […]
DURHAM, N.C., April 14, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the closing of a secured debt financing facility with Silicon Valley Bank for up to $50 million, of which the first $20 million was […]
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Jeffrey Lawson MD, PhD has been appointed President and Chief Executive Officer. Carrie S. Cox has assumed the role of Executive Chairman. Dr. Lawson, an innovator, scientist and vascular surgeon has been involved in the […]
